u/Electronic_Date_7056

Update: only 4 men left! If there are any folks out here that are available to try joining the study, we'd very much appreciate it. Thanks!

Hey guys, wanted to thank everyone who commented and who joined our study!

We're only 7 men away from closing the study.

I know a few of the other members weren't enthused about the $125 study compensation. Everyone participating is helping to support development of better GLP-1s with fewer side effects.

Thanks, gents

Are you an adult in the US currently using an FDA-approved GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/bxoij1bmbj1h1.jpg?width=277&format=pjpg&auto=webp&s=1851eb1b7e04ec7df88ce1b87d383506378afb83

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com

Hey guys, was just invited to this community. I'm working in clinical research supporting GLP-1 development. I'm going to crosspost a study invitation here. We're looking for men to join, would love to as many folks join the study. Thanks!

Are you an adult in the US currently using an FDA-approved GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/9mkfv9rwwi1h1.jpg?width=277&format=pjpg&auto=webp&s=cb96390b352bc349ac43a9466d45e78c52c20f45

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com

Are you an adult in the US currently using an FDA-approved GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/kb1iafa5ab1h1.jpg?width=277&format=pjpg&auto=webp&s=76cc2f707d25921158e467f340d0060174c9efec

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com

Are you an adult in the US currently using an FDA-approved GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/kb1iafa5ab1h1.jpg?width=277&format=pjpg&auto=webp&s=76cc2f707d25921158e467f340d0060174c9efec

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com

Are you an adult in the US currently using an FDA-approved GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/9u9g3jy6xrzg1.png?width=265&format=png&auto=webp&s=95bb20fd294a0f74f1cfe723633053add88ca059

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com

Are you an adult in the US currently using an FDA-approved GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/jxzui85dvkzg1.png?width=377&format=png&auto=webp&s=15b698f787b757081db6b914ae81fe9a79a01bc1

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com

Hi guys,

My clinical research firm is doing a bunch of studies in this space. I'd like to place an invitation to a current survey that we're doing for Zepbound users. All of our research is approved by IRB with results published in academic publications.

All of our research compensates participants for participating.

Thanks!

Are you an adult in the US currently using an FDA-approved GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/csvtp245x4zg1.png?width=164&format=png&auto=webp&s=02bdb3bbc3c5fc5fe8bb5eebbabef35fd7043271

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com

Are you an adult in the US currently using an FDA-approved GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/ba93crf8btyg1.png?width=300&format=png&auto=webp&s=55d28707e34229723cf7bea81cca541145158905

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com

Are you an adult in the US currently using an FDA-approved weekly GLP-1 medication for weight management? You may be eligible to participate in a research study.

Bridge Access Solutions (BAS) is conducting a research study with individuals currently prescribed a GLP-1 medication to gain insight into real-world participant experiences and to identify unmet needs.

• What’s Involved: Completion of an electronic, 8–10-minute daily diary over a period of 6 weeks. You will be asked questions about your experience with any GI symptoms (nausea, vomiting, diarrhea) and food/appetite, relative to your weekly GLP-1 dose.
• Eligibility: 18+ US adults with a BMI of 30 or greater (when you started treatment), currently using a GLP-1 medication without diabetes.
• Compensation: $125 upon study completion.
• When: Enrollment begins mid-March 2026.
• Privacy: Your feedback will be de-identified, and reasonable steps will be taken to protect your privacy. If you qualify and choose to participate, you may be asked to authorize access to relevant medical records.

If you are interested, complete our online screener, scan the QR code or visit:

https://20250159GLP1.studyenrollment.com/  

https://preview.redd.it/9ziwmiw2jqyg1.png?width=139&format=png&auto=webp&s=af3013388082cd63b7556976f4b6fe2e2e47ea15

This is not a clinical trial and does not involve medical treatment or advice. Your GLP-1 medication will not change, nor will a different medication be provided as part of your participation in this study. The cost of your GLP-1 medication will not be covered through your participation in this study.

Questions?

Call or text: (385) 786-6831

Email: research@bridgeaccesssolutions.com